Fresh analysis suggests that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end traditional lifestyle regimens.
Published data in a prominent health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals using such drugs must be aware of the potential of quick rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to starting weight in about 18 months.
Analyzing Therapies
The research, which reviewed 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with conventional dieting.
The team emphasize that individuals who shed pounds through dieting usually experience a slower creep back—around 100 grams monthly—once they finish.
Explaining the Quick Regain
Doctors suggest the way of the drugs is key to understanding the heightened rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the body to produce less of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making overeating far more likely."
A Chronic Issue?
Medical guidelines suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals contend that, given the likelihood of relapse, the treatment is often long-term.
This perspective is echoed by pharmaceutical companies, who say that the findings "underscore the persistent character of excess weight," similar to managing diseases like hypertension.
Patient Accounts
Users who have come off the jabs describe a intense return of appetite.
"It was like a switch activating and I was suddenly ravenous," described an individual.
This challenge is worsened if individuals have not established permanent lifestyle or habit modifications during treatment.
Growing Interest
Recent estimates suggest that a significant number of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among women than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on integrated lifestyle management.
